Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 92.32K shares, a 81.10% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 88.93K shares, a 1.01% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 261.14K shares, a 29.20% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 151.49K shares, a 89.09% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 990.93K shares, a 76.30% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 4.18M shares, a 401.99% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 832.91K shares, a 165.03% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 314.27K shares, a 113.07% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 92.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 593.88K shares derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 88.93K shares 10-Q · filed 2026-05-11 | 990.02K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 261.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 990.93K shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 151.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.10M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 488.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | 2.34M shares derived: sum of 4 quarters · filed 2025-07-28 |
| 2025-03-31 | 89.83K shares 10-Q · filed 2025-05-08 | 2.41M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 368.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 4.18M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 1.39M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 3.85M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 564.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 2.59M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 1.86M shares 10-Q · filed 2024-05-02 | 2.46M shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 42.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 832.91K shares 10-K · filed 2024-03-05 |
| 2023-09-30 | 125.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | 1.04M shares derived: sum of 4 quarters · filed 2023-10-30 |
| 2023-06-30 | 432.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 937.24K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 232.29K shares 10-Q · filed 2023-05-11 | 536.98K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 252.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 314.27K shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 19.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 87.87K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 32.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 168.20K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 9.58K shares 10-Q · filed 2022-05-02 | 145.92K shares derived: sum of 4 quarters · filed 2022-05-02 |
| 2021-12-31 | 26.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 147.50K shares 10-K · filed 2022-03-10 |
| 2021-09-30 | 99.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 122.72K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 10.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2021-03-31 | 11.16K shares 10-Q · filed 2021-05-06 | |
| 2020-12-31 | 1.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 32.20K shares 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |